Downloads
-
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
4/25/2024
BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months.
-
Integrating Quality Processes And Documentation After A Merger
4/25/2024
If your company is undergoing a merger, you must juggle operations while ensuring minimal disruptions. You'll need a holistic view of QMS and SOPs to harmonize procedures.
-
Clone, Strain, And Viral Construct Screening Executed For You
4/24/2024
Evaluate your clones, strains, and viral constructs in our bioreactors with flexible scale out.
Benefits
Select the best clone by evaluating larger experimental cohorts
Make the most informed, data-driven selection by leveraging our fleet of 250mL and 5L Culture bioreactors to screen your clones, strains and viral constructs.
Defer your capital equipment spend
Evaluate your clones, strains and viral constructs without the need for new capital equipment.
Transparent, real-time data provided by a team of experts
Painless technology transfer with live data relayed via our cloud-connected systems. We have >95% success rate with >22,000 runs successfully executed.
-
Leverage Bioreactor Capacity When You Need It With Culture Bioreactors
4/24/2024
Gain access to Culture bioreactors when you need rapid overflow experimental capacity.
Benefits
Progress studies faster
Run overflow projects and conduct parallel experiments with Culture to reduce time and alleviate bottlenecks.
Stay agile in your capacity planning
Scale your workload at Culture according to your current needs. Respond rapidly to surging demands.
Eliminate your capital equipment spend
Leverage Culture’s facility quickly to avoid building out lab space, spending capital on equipment, and hiring specialized staff.
-
NK Cell Therapies: How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach
4/24/2024
We caught up with Chris Horan, Artiva Biotherapeutics' CTO, to discuss natural killer cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.
-
Improving Governance And Compliance With Knowledge Management
4/23/2024
Knowledge management — it’s not just a soulless exercise. In the last part of his series, Hirsh helps bridge the gap between compliance and business needs.
-
Greener Detergents For Biopharmaceutical Applications
4/22/2024
Explore a portfolio of best-in-class detergent alternatives to Triton™ X-100 for use in biomanufacturing applications.
-
Sf9 Cell Suspension Culture In Corning® Insect Cell Serum-Free Medium
4/22/2024
Explore the information gathered when the growth of Sf9 insect cells was studied in three different mediums.
-
Powdered Media For Cell Culture And Bioprocessing
4/22/2024
Corning now provides an extensive lineup of powdered basal and specialty media to complement our liquid media offering including popular DMEM, MEM, and RPMI formulations.
-
Vero Cell Culture In Corning® Dry Powder Vero Serum-free Medium
4/22/2024
This study compares a serum-free medium to other commercially available pre-hydrated media to measure it's effectiveness in supporting the culture of adherent Vero cells.